1. Market Research
  2. > Pharmaceutical Market Trends
COVID-19 Therapy and Vaccine Drug Pipeline Market Report- September 2020 Update

COVID-19 Therapy and Vaccine Drug Pipeline Market Report- September 2020 Update

  • September 2020
  • 512 pages
  • ID: 5968524
  • Format: PDF
  • VPAResearch

Summary

Table of Contents

The September 2020 updated COVID-19 report identifies 440 companies investing in therapy and vaccination products. Around 24 companies have advanced their products into Phase 3 and around 15 companies are in Phase 2/3. Pipeline candidates of 114 companies are in phase 1 or phase 2. 23 companies are in IND/CTA filed phase.

The early development COVID-19 product pipeline is much stronger with 135 companies investing their R&D resources in preclinical COVID, 127 companies developing Research phase products.
The research report is a comprehensive market research on COVID-19 pipeline products detailing the companies, drug and vaccine candidates, their current status, historical developments and other progress.

The COVID pandemic is resulting in significant health and economic impact on individuals and businesses across the world. Accordingly, companies like Inovio, Pfizer, Johnson and Johnson, Novavax are forming joint ventures, GlaxoSmithKline is extending access to vaccine adjuvant platform, and Sanofi is sharing its expertise with BARDA among others.

Following the release of SARS-CoV-2 genome sequence, majority of companies ranging from severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) are focusing on vaccine candidates for COVID-19.

Report Highlights
- The current COVID-19 pipeline is characterized by active operations of 24 companies including large players - AbCellera Biologics, Ansun Biopharma, AryoGen, AstraZeneca, Bellerophon Therapeutics, Biocad, CytoDyn, Eli Lilly and Company, FUJIFILM Toyama Chemical, Fulcrum Therapeutics, Gilead Sciences, Insmed Inc, International Biotech Center, Kowsar Biotechnology, Moderna Therapeutics, Octapharma, OncoImmune, Regeneron Pharmaceuticals, Romark Laboratories, Serum Institute of India, Sinovac Biotech, Swedish Orphan Biovitrum AB, Vanda Pharmaceuticals, Wuhan Institute of Biological Products.
- Over half of the products are new molecular entities (NMEs)
- Pre-clinical and research phase companies offer huge opportunities for mergers, acquisitions and partnership options.
- Leading mechanism of action of most products include Interleukin 6 inhibitors
- 12 products present significant potential for development during 2020.

Scope of the Report
- 440 companies and products analyzed in the research
- Drug candidate, Vaccine candidate details including current status, companies involved, new molecular entity, phase, mechanism of action, recent developments, route of administration and other details analyzed for each candidate
- New molecular entities identified
- Clinical trials and related details provided for COVID-19 product candidates
- Recent COVID-19 pipeline developments in the industry are detailed

Companies included in the research

Phase 3-
AbCellera Biologics Inc , Ansun Biopharma Inc, AryoGen, AstraZeneca Plc, Bellerophon Therapeutics, Biocad, CytoDyn Inc, Eli Lilly and Company, FUJIFILM Toyama Chemical Co Ltd, Fulcrum Therapeutics, Gilead Sciences Inc, Insmed Inc, International Biotech Center Generium, Kowsar Biotechnology, Moderna Therapeutics Inc, Octapharma, OncoImmune Inc, Regeneron Pharmaceuticals Inc, Romark Laboratories LC, Serum Institute of India Ltd, Sinovac Biotech Ltd, Swedish Orphan Biovitrum AB, Vanda Pharmaceuticals Inc, Wuhan Institute of Biological Products Co Ltd, Abivax SA, Beijing Defengrei Biotechnology, Biohaven Pharmaceuticals Inc, BioNTech SE, Biophytis SA, Evelo Biosciences, FibroGen Inc, Immunic Inc, Inmunova SA, NeuroActiva Inc, Ono Pharmaceutical Co Ltd, PTC Therapeutics Inc, RedHill Biopharma Ltd, Swedish Orphan Biovitrum AB, Thirty respiratory Ltd

Phase 2-
4D Pharma PLC, AB Science, Acerta Pharma B.V., AI Therapeutics, Aldeyra Therapeutics Inc, Altum Pharmaceuticals Inc, Amarin Corp, Anhui Zhifei Longcom Biopharmaceutical, Apeiron Biologics GMBH, Applied Therapeutics Inc, Ascletis Pharma Inc, AstraZeneca Plc, Atea Pharmaceuticals Inc, aTyr Pharma Inc, Beech Tree Labs, BeiGene, BerGenBio SA, Blade Therapeutics Inc, Boehringer Ingelheim, Bristol-Myers Squibb Co, Bukwang Pharm Co Ltd, CalciMedica Inc, Can-Fite BioPharma Ltd, CinnaGen Co, Confluence Life Sciences Inc, Constant Therapeutics LLC, Eiger BioPharmaceuticals Inc, Eli Lilly and Company, Galecto Biotech, Genentech, GeneOne Life Science Inc, Globavir Biosciences Inc, Grifols SA, Heber Biotech SA, Heron Therapeutics Inc, Hope Biosciences LLC, Immune Therapeutics Inc, Inotrem SAA, Janssen Pharmaceuticals, Kancera AB, Karyopharm Therapeutics Inc, Kinevant Sciences Ltd, Laurent Pharmaceuticals Inc, Merck & Co, NeuroClear Technologies Inc, Novartis, Novartis AG, Novavax Inc, Pfizer Inc, PharmaMar SA, Pharming Group NV, PhaseBio Pharmaceuticals Inc, Pulmotect Inc, Reata Pharmaceuticals Inc, Relief Therapeutics Holdings AG, Renibus Therapeutics Inc, resTORbio Inc, Ridgeback Biotherapeutics LP, Roche AG, Rovi Corp, sanofi aventis, Sanotize Research and Development Corp, Synairgen Plc, Tianjin CanSino Biotechnology Inc, Tobira Therapeutics Inc, UCB Pharma, Vicore Pharma Holding AB , Viriom Inc, Vitaeris Inc, Xenothera, Zydus Cadila, Akari Therapeutics Plc, Arcturus Therapeutics Holdings Inc , Bharat Biotech International Ltd, Celularity Inc, Genexine Inc, I-MAB Biopharma Co Ltd, Immunitor Inc, Inovio Pharmaceuticals Inc, Janssen Pharmaceuticals, Janssen Vaccines and Prevention B.V, Kamada Ltd, Pacific Meinuoke Bio Pharmaceutical, Takara Bio Inc, Telios Pharmaceuticals Inc

Phase 1-
Ampio Pharmaceuticals Inc, argenx SE, AstraZeneca Plc, Atossa Therapeutics Inc, BioCryst Pharmaceuticals Inc, Brii Biosciences Ltd, Celltrion Inc, Clear Creek Bio, Clover Biopharmaceuticals Inc, Corvus Pharmaceuticals Inc, CureVac AG, Denali Therapeutics Inc, Dynavax Technologies Corp, Enlivex Therapeutics Ltd, ExeGi Pharma LLc, Fate Therapeutics Inc, Genexine Inc, Helperby Therapeutics Group Ltd , ImmuneMed Inc, Izana Bioscience, Medicago Inc, Palatin Technologies Inc, Pluristem Therapeutics Inc, ReiThera Srl, SAB Biotherapeutics Inc, Shanghai Junshi Bioscience Co Ltd, Sinocelltech Ltd, Themis Bioscience GmBH, Vaxine Pty Ltd, ychan Pte. Ltd.

IND/CTA Filed-
Agenus Inc, Algernon Pharmaceuticals Inc, Altimmune Inc, Better Life Pharmaceuticals Inc, Capricor Therapeutics, CytoAgents, Daewoong Pharmaceutical Co Ltd, Diffusion Pharmaceuticals Inc, Ensysce Biosciences Inc, GLW Pharma, ImmunityBio Inc, Kazia Therapeutics Ltd, Komipharm International Co Ltd, NovaLead Pharma Pvt Ltd, Novoteris LLC, Oncology Venture US, Organicell Regenerative Medicine Inc, Personalized Stem Cells Inc, Sun Pharmaceutical Industries Ltd, TC BioPharm Ltd, Union Therapeutics AS, VSY Biotechnology BV, Walvax Biotechnology Co Ltd

Preclinical-
60 Degrees Pharmaceuticals, 7 Hills Pharma LLC, AbbVie Inc, Abnova Corporation, Abound Bio, Acer Therapeutics Inc, Adagio Therapeutics, Adaptive Phage Therapeutics, AdaptVac, AIM ImmunoTech Inc, Akers Biosciences Inc, Aldeyra Therapeutics Inc, Anivive Lifesciences, Aptorum Group Limited, AriBio Co Ltd, Aridis Pharmaceuticals Inc, ARMS Pharmaceutical LLC, Array BioPharma Inc, AstraZeneca Plc, Atossa Therapeutics Inc, Berlin Cures Holding AG, Beyond Air Inc, BeyondSpring Inc, BioNet- Asia Co Ltd, BioNtech SE, Bio-Thera Solutions, BlueSky Immunotherapies, Bolder BioTechnology, Capricor Therapeutics Inc, CEL-SCI Corporation, Centivax, Chimeron Bio, ChromaDex, Cidara Therapeutics Inc, Cocrystal Pharma Inc, Codagenix Inc, COVAXX, COVID-19 Vaccine Corporation, Daiichi Sankyo Co Ltd, Delta 4, Dilafor AB, Dong Wha Pharmaceutical, Eagle Pharmaceuticals Inc, Elixirgen Therapeutics Inc, Emergent BioSolutions Inc, ENDECE LLC, Ennaid Therapeutics LLC, Entos Pharmaceuticals Inc, EpicentRx Inc, Epitopoietic Research Corporation, EpiVax Inc, eTheRNA Immunotherapies NV, EUCYT Laboratories LLC, Excision BioTherapeutics, ExeVir Bio, FibroGenesis LLC, FirstWave Bio, Flow Pharma Inc, GeneOne Life Science, GeoVax Labs, GigaGen Inc, Ginkgo Bioworks, Glycovax Pharma, GRDG Sciences, Grifols SA, HaloVax LLC, Heat Biologics Inc, HiFiBiO, Hoth Therapeutics, iBio Inc, IDBiologics Inc, IGY Life Sciences, Immodulon Therapeutics, IMV Inc, Inimmune, Innovation Pharmaceuticals Inc, INTELLiSTEM Technologies Inc, Isotechnika, Joseah Biopharma, Lineage Cell Therapeutics, LineaRx Inc, MedinCell S.A., Meissa Vaccines Inc, Memgen Corp, Merck & Co, Molecular Partners AG, Moleculin Biotech inc, Ology Bioservices Inc, Oncogenuity Inc, Oncology Venture, Oncolys BioPharma, Onconova Therapeutics, Oragenics Inc, OSE Immunotherapeutics, OyaGen Inc, PDS Biotechnology Corporation, PepTC Vaccines Limited, Precision NanoSystems Inc, Primmune Therapeutics Inc, Proteostasis Therapeutics Inc, Providence Therapeutics, Q BioMed Inc, Qualigen Therapeutics Inc, Radikal Therapeutics Inc, Rapa Therapeutics, Regeneron Pharmaceuticals Inc, Repurpose AI, Resverlogix Corp, RNAimmune Inc, Saiba AG, Sanofi pasteur, Sanofi SA, Secarna Pharmaceuticals GmbH&Co.KG, Selva Therapeutics, Senhwa Biosciences, Senzer Pharmaceuticals, Shanghai Junshi Biosciences Co Ltd, SK bioscience, Sorrento Therapeutics Inc, Spring Bank Pharmaceuticals Inc, Stabilitech Biopharma Ltd, Starpharma Holdings Ltd, Stemirna Therapeutics Co Ltd, Tonix Pharmaceuticals Holding Corp, UbiVac LLC, Vaxart Inc, Vaxil Bio Ltd, VBI Vaccines Inc, Verndari Inc, Vir Biotechnology Inc, Vivtex Corporation, Xiamen Innovax Biotech, YUMAB Gmbh, Zhittya Genesis Medicine, Zydus Cadila

Research-
48Hour Discovery Inc, A2A Pharmaceuticals Inc, Active Motif Inc, Adaptive Biotechnologies Inc, AdaptVac, Affinity Biosciences, AffyXell Therapeutics, AIkido Pharma Inc, Airway Therapeutics Inc, AJ Vaccines A/S, Akshaya Bio Inc, Aldevron, Aligos Therapeutics Inc, Alkido Pharma Inc, Amarillo Biosciences Inc, ANA Therapeutics, Anixa Biosciences Inc, Applied Biology Inc, Arbutus Biopharma Corp, Arrowhead Pharmaceuticals Inc, ARTES Biotechnology Gmbh, AstraZeneca Plc, Atreca Inc, AUM LifeTech Inc, Avacta Life Sciences Limited, Avalon GloboCare Corp, AvantGen Inc, Axon Neuroscience SE, Biocad, Biological E. Limited, Bioxytran Inc, Bold Therapeutics Inc, BriaCell Therapeutics Corp, CellPoint LLC, Chugai Pharmabody Research, Cobra Biologics Ltd, Codagenix Inc, Codiak BioSciences Inc, Cytovia Therapeutics Inc, Cyxone AB, Dyadic International Inc, Emergent BioSolutions Inc, Emergex vaccines Ltd, EpiVax Inc, Evotec Biologics, Exscientia Ltd, Generex Biotechnology Corp, Glycovax Pharma Inc, GT Biopharma, Hemogenyx Pharmaceuticals Plc, Hetero Labs Ltd, HiFiBiO Therapeutics, Hoth Therapeutics Inc, ImmuneCyte Inc, Immunomic Therapeutics Inc, ImmunoPrecise Antibodies Ltd, Imophoron Ltd, ImStem Biotechnology, Intravacc, Iontas Ltd, IVIEW Therapeutics Inc, Jiangsu Alphamab Biopharmaceuticals, kali-extracts Inc, Kleo Pharmaceuticals Inc, Ligandal Inc, Mabpharm Ltd, Manhattan BioSolutions LLC, Mateon Therapeutics Inc, Medivir AB, Memo Therapeutics AG, MigVax Ltd, Mymetics Corporation, NanoViricides Inc, Nascent Biotech Inc, Neovii Biotech, Neurimmune AG, Neutrolis Therapeutics, NuGenerex Immuno-Oncology Inc, OliX Pharmaceuticals Inc, OncoSec Medical Inc, Orgenesis Inc, OSIVAX, Panacea Biotec Ltd, PeptiDream Inc, Pfizer Inc, Phylex BioSciences Inc, Phytoption LLC, Pneumagen Ltd, Predictive Oncology, Prellis Biologics Inc, Prismic Pharmaceuticals, Qurient Co Ltd, Recce Pharmaceuticals, Regeneron Pharmaceuticals Inc, Replicate Bioscience, Sanofi Pasteur, Sarepta Therapeutics Inc, Scancell Holdings plc, Sirnaomics Inc, Sirona Biochem Corp, SmartPharm Therapeutics Inc, Soligenix Inc, SOM Biotech, Sosei Heptares, Sunshine Biopharma Inc, Synlogic Inc, Takeda, Takeda Pharmaceutical Company Ltd, Takis Biotech, Tetra Bio Pharma, Tevogen Bio, TFF pharmaceuticals Inc, Twist Bioscience Corp, Ufovax Inc, UMN Pharma Inc, United Biomedical Inc, Valneva SE, Valo Therapeutics Ltd, Vanda Pharmaceuticals Inc, Vaxil BioTherapeutics, Vir Biotechnology Inc, Viravaxx AG, Virna therapeutics, Vyripharm Biopharmaceuticals, WuXi Biologics Inc, Xbiotech, XORTX Therapeutics Inc

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Mycoplasma Testing Market by Product & Service, Technique, Application, End User, Region - Global Forecast to 2025

  • $ 4950
  • November 2020
  • 150 pages

The global mycoplasma testing market size is valued at an estimated USD 689 million in 2020 and is projected to reach USD 1,095 million by 2025, at a CAGR of 9.7% during the forecast period. The global ...

  • United States
  • World
  • Life Sciences
  • Pharmaceutical
  • Industry analysis
  • Biologics Production
  • Health Expenditure

ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on